Insmed Gene Therapy LLC

Clinical trials sponsored by Insmed Gene Therapy LLC, explained in plain language.

Now part of Insmed Incorporated INSM NASDAQ

A subsidiary of Insmed focused on gene therapy for rare diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 1

Gene therapy injection aimed at slowing ALS enters human testing

Disease control Recruiting now

This early-stage trial is testing a single injection of a gene therapy called INS1202, given into the spinal fluid, for people with ALS (Lou Gehrig's disease). The study includes 23 adults, some with a specific genetic mutation (SOD1) and some without known genetic causes. The ma…

Phase 1 • Sponsor: Insmed Gene Therapy LLC • Aim: Disease control

Last updated Sep 03, 2026 00:00 UTC

Insmed Gene Therapy LLC

Gene therapy injection aimed at slowing ALS enters human testing